BEVYXXA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Bevyxxa, and what generic alternatives are available?
Bevyxxa is a drug marketed by Portola Pharms Inc and is included in one NDA. There are five patents protecting this drug.
This drug has sixty-eight patent family members in twenty-six countries.
The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.
DrugPatentWatch® Generic Entry Outlook for Bevyxxa
Bevyxxa was eligible for patent challenges on June 23, 2021.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 29, 2031. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for BEVYXXA
| International Patents: | 68 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 82 |
| Patent Applications: | 481 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for BEVYXXA |
| DailyMed Link: | BEVYXXA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for BEVYXXA
Generic Entry Date for BEVYXXA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for BEVYXXA
US Patents and Regulatory Information for BEVYXXA
BEVYXXA is protected by six US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of BEVYXXA is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting BEVYXXA
Pharmaceutical salts and polymorphs of a factor Xa inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: INHIBITING COAGULATION
Methods of using crystalline forms of a salt of a factor Xa inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
Methods of using crystalline forms of a salt of a factor Xa inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: PROPHYLAXIS OF VENOUS THROMBOSIS
Methods of synthesizing factor Xa inhibitors
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Pharmaceutical salts and polymorphs of a factor Xa inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: PROPHYLAXIS OF PULMONARY EMBOLISM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-001 | Jun 23, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-002 | Jun 23, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-002 | Jun 23, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-002 | Jun 23, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-001 | Jun 23, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-001 | Jun 23, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BEVYXXA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-002 | Jun 23, 2017 | ⤷ Try a Trial | ⤷ Try a Trial |
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-001 | Jun 23, 2017 | ⤷ Try a Trial | ⤷ Try a Trial |
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-002 | Jun 23, 2017 | ⤷ Try a Trial | ⤷ Try a Trial |
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-002 | Jun 23, 2017 | ⤷ Try a Trial | ⤷ Try a Trial |
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-001 | Jun 23, 2017 | ⤷ Try a Trial | ⤷ Try a Trial |
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-001 | Jun 23, 2017 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for BEVYXXA
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Portola Pharma UK Limited | Dexxience | betrixaban | EMEA/H/C/004309 Prevention of venous thromboembolism |
Refused | no | no | no | 2018-09-20 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for BEVYXXA
When does loss-of-exclusivity occur for BEVYXXA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 07333377
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 71502
Estimated Expiration: ⤷ Try a Trial
Patent: 13963
Estimated Expiration: ⤷ Try a Trial
China
Patent: 1652136
Estimated Expiration: ⤷ Try a Trial
Patent: 5193799
Estimated Expiration: ⤷ Try a Trial
Colombia
Patent: 20933
Estimated Expiration: ⤷ Try a Trial
Costa Rica
Patent: 914
Estimated Expiration: ⤷ Try a Trial
Ecuador
Patent: 099501
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 01760
Estimated Expiration: ⤷ Try a Trial
Hong Kong
Patent: 34031
Estimated Expiration: ⤷ Try a Trial
Israel
Patent: 9219
Estimated Expiration: ⤷ Try a Trial
Morocco
Patent: 086
Estimated Expiration: ⤷ Try a Trial
New Zealand
Patent: 8180
Estimated Expiration: ⤷ Try a Trial
Nicaragua
Patent: 0900145
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 01760
Estimated Expiration: ⤷ Try a Trial
Russian Federation
Patent: 52484
Estimated Expiration: ⤷ Try a Trial
Patent: 09126147
Estimated Expiration: ⤷ Try a Trial
Patent: 12104816
Estimated Expiration: ⤷ Try a Trial
Singapore
Patent: 201504425S
Estimated Expiration: ⤷ Try a Trial
South Africa
Patent: 0904758
Estimated Expiration: ⤷ Try a Trial
South Korea
Patent: 1472765
Estimated Expiration: ⤷ Try a Trial
Patent: 090107499
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 09090
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering BEVYXXA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Hong Kong | 1115131 | PHARMACEUTICAL SALTS AND POLYMORPHS OF N-(5-CHLORO-2-PYRIDINYL)-2-[[4- [(DIMETHYLAMINO)IMINOMETHYL]BENZOYL]AMINO]-5-METHOXY-BENZAMIDE , A FACTOR XA INHIBITOR | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 0164642 | ⤷ Try a Trial | |
| Germany | 60040676 | ⤷ Try a Trial | |
| Denmark | 1259485 | ⤷ Try a Trial | |
| Japan | 2009514976 | ⤷ Try a Trial | |
| China | 101304971 | Pharmaceutical salts and polymorphs of n- (5-chl0r0-2-pyridinyl) -2- [ [4- [ (dimethylamino) iminomethyl] benzoyl] amino] -5-meth oxy-benzamide, a factor xa inhibitor | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
